In ₹ Crore except Per Share Latest Annual | ALIVUS FY24 | DIVISLAB FY26 | AARTIDRUGS FY26 | AKUMS FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | 97.31× | ◆ 20.46× | 44.99× | 44.99× | |
| P/B | — | 14.89× | ◆ 2.57× | 3.45× | 3.45× | |
| EV/EBITDA | — | 72.47× | ◆ 14.74× | 21.40× | 21.40× | |
| Market Cap | — | ₹2.49L Cr | ₹3,988 Cr | ₹11,483 Cr | ₹11,483 Cr | |
| Growth | ||||||
| Revenue CAGR 3Y | — | ◆ 10.78% | -1.89% | — | 4.44% | |
| Revenue CAGR 5Y | — | ◆ 8.67% | 3.55% | — | 6.11% | |
| Net Income CAGR 3Y | — | ◆ 12.09% | 5.43% | — | 8.76% | |
| Revenue YoY (latest Q) | — | ◆ 27.80% | 19.01% | 13.93% | 19.01% | |
| Net Income YoY (latest Q) | — | ◆ 65.50% | -7.12% | 56.11% | 56.11% | |
| Profitability | ||||||
| EBITDA Margin | 29.53% | ◆ 32.59% | 12.05% | 11.98% | 12.05% +145% | |
| Net Income Margin | 20.62% | ◆ 24.32% | 7.60% | 5.88% | 7.60% +171% | |
| Return on Common Equity | ◆ 20.19% | 15.32% | 12.58% | 7.66% | 12.58% +60% | |
| Return on Capital Employed | ◆ 25.74% | 16.55% | 12.80% | 8.44% | 12.80% +101% | |
| Return on Assets | ◆ 16.52% | 12.82% | 6.92% | 4.71% | 6.92% +139% | |
| Credit & Quality | ||||||
| Total Debt/Equity | — | ◆ 0.00× | 0.37× | 0.02× | 0.02× | |
| Interest Coverage | ◆ 401.55× | 129.48× | 7.19× | 3.91× | 7.19× +5485% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹2,283 Cr | ₹10,560 Cr | ₹2,565 Cr | ₹4,359 Cr | ₹4,359 Cr -48% | |
| Net Income | ₹471 Cr | ₹2,568 Cr | ₹195 Cr | ₹256 Cr | ₹256 Cr +84% | |
| Total Assets | ₹2,850 Cr | ₹20,033 Cr | ₹2,815 Cr | ₹5,447 Cr | ₹5,447 Cr -48% | |
| EPS | — | ₹96.75 | ₹21.36 | ₹16.67 | ₹21.36 | |
| Book Value per Share | — | ₹632.49 | ₹169.74 | ₹217.57 | ₹217.57 | |